PT - JOURNAL ARTICLE AU - Gholamrezaei, Ali AU - Magee, Michael R AU - McNeilage, Amy G AU - Dwyer, Leah AU - Sim, Alison AU - Ferreira, Manuela L AU - Darnall, Beth D AU - Brake, Timothy AU - Aggarwal, Arun AU - Craigie, Meredith AU - Hollington, Irina AU - Glare, Paul AU - Ashton-James, Claire E TI - A digital health intervention to support patients with chronic pain during prescription opioid tapering: a pilot randomised controlled trial AID - 10.1101/2023.05.10.23289771 DP - 2023 Jan 01 TA - medRxiv PG - 2023.05.10.23289771 4099 - http://medrxiv.org/content/early/2023/05/11/2023.05.10.23289771.short 4100 - http://medrxiv.org/content/early/2023/05/11/2023.05.10.23289771.full AB - Introduction: Recent changes in opioid prescribing guidelines have led to an increasing number of patients with chronic pain being recommended to taper. However, opioid tapering can be challenging, and many patients require support.Objectives: We evaluated the feasibility, acceptability, and potential efficacy of a co-designed psycho-educational video and SMS text messaging intervention to support patients with chronic pain during prescription opioid tapering.Methods: A pilot randomised controlled trial was conducted. In addition to their usual care, participants in the intervention group received a psycho-educational video and 28 days of text messages (two SMS/day). The control group received usual care. The feasibility, acceptability, and potential efficacy of the intervention were evaluated. The primary outcome was opioid tapering self-efficacy. Secondary outcomes were pain intensity and interference, anxiety and depression symptom severity, pain catastrophising, and pain self-efficacy.Results: Of 28 randomised participants, 26 completed the study (13 in each group). Text message delivery was 99.2% successful. Most participants rated the messages as useful, supportive, encouraging, and engaging, 78.5% would recommend the intervention to others, and 64% desired a longer intervention period. Tapering self-efficacy (Cohen’s d = 0.74) and pain self-efficacy (d = 0.41) were higher and pain intensity (d = 0.65) and affective interference (d = 0.45) lower in the intervention group at week 4.Conclusions: It is feasible, acceptable, and potentially efficacious to support patients with chronic pain during prescription opioid tapering with a psycho-educational video and SMS text messaging intervention. A definitive trial has been initiated to test a 12-week intervention.Competing Interest StatementDr. Darnall is Chief Science Advisor at AppliedVR, and her consulting role with this company (personal fees) is unrelated to the current research. Dr. Darnall receives royalties for four pain treatment books she has authored or co-authored. She is the current principal investigator for two pain research awards from the Patient-Centered Research Outcomes Research Institute and two NIH pain research grants. She serves on the Board of Directors for the American Academy of Pain Medicine, the Board of Directors for the Institute for Brain Potential, and the Medical Advisory Board for the Facial Pain Association. Dr. Darnall is a scientific member of the NIH Interagency Pain Research Coordinating Committee, a former scientific member of the Centers for Disease Control and Prevention Opioid Workgroup (2020 2021), and a current member of the Pain Advisory Group of the American Psychological Association. Other Authors have no conflict of interest.Clinical TrialACTRN12621000795897Clinical Protocols https://bmjopen.bmj.com/content/12/4/e057174 https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=381757&isReview=true Funding StatementThis research was supported by a philanthropic gift to The University of Sydney from the Ernest Heine Family Foundation. The study funder and sponsor had no role in the study design, data collection, analysis, and interpretation, or in preparing the final report. BDD acknowledges support from the National Institutes of Health NIDA K24-DA053564.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Northern Sydney Local Health District Research and Ethics Committee (ID number 2020/ETH03288) and pre-registered with the Australian New Zealand Clinical Trials Registry (registration number ACTRN12621000795897).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesIndividual data produced in the present study are not available to maintain patient confidentiality. SAS codes and output tables and additional analysis may be provided upon reasonable request to the authors.